USPTO Art Unit 1624 Prosecution Statistics

Art Unit Information

Art Unit: 1624
Group: 1620
Tech Center: 1600
Total Cases: 29,126
Last Active: November 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19382964METHOD FOR MAKING METHANE FROM CARBON DIOXIDENovember 2025March 2026Allow400NoNo
19383003METHOD FOR MAKING A BENZIMIDAZOLENovember 2025March 2026Allow400NoNo
19327881MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOFSeptember 2025January 2026Allow410YesNo
19240239HETEROARYL COMPOUNDS, SOLID FORMS, PREPARATION METHODS AND USES THEREOFJune 2025February 2026Allow811YesNo
19223498SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOFMay 2025January 2026Allow821YesNo
19213875SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORSMay 2025August 2025Allow310NoNo
19205807SUBSTITUTED 1',2'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,4'-PYRIMIDO[5',4':4,5]PYRROLO[2,1-c][1,2,4]TRIAZIN]-3'-ONES AS CYCLIN-DEPENDENT KINASE INHIBITORSMay 2025October 2025Allow510YesNo
19183531TARGETED PROTEIN DEGRADATIONApril 2025July 2025Allow201NoNo
19091638FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOFMarch 2025July 2025Allow300NoNo
19088795REVERSIBLE DPP1 INHIBITORS AND USES THEREOFMarch 2025August 2025Allow411YesNo
19083274HETEROCYCLIC GLP-1 AGONISTSMarch 2025December 2025Allow911NoNo
19079297CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOFMarch 2025November 2025Allow811YesNo
19076644SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USESMarch 2025October 2025Allow711NoNo
19072824(R)-N-(4-(CHLORODIFLUOROMETHOXY)PHENYL)-2-(DIFLUOROMETHYL)-1-(1-HYDROXYPROPAN-2-YL)-7-(PYRIMIDIN-5-YL)-1H-BENZO[D]IMIDAZOLE-5-CARBOXAMIDE, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR TAUTOMER THEREOF, FOR TREATING CERTAIN LEUKEMIASMarch 2025September 2025Allow610YesNo
19071647CANCER TREATMENTS USING MODIFIED FATTY ACIDS AND THE CARRIERS TO ADMINISTER THEMMarch 2025July 2025Allow420NoNo
19071155FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTSMarch 2025August 2025Allow501NoNo
19069098MACROCYCLIC DERIVATIVE AND USE THEREOFMarch 2025June 2025Allow301NoNo
19058521PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORSFebruary 2025September 2025Allow711YesNo
19052553THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOFFebruary 2025June 2025Allow410NoNo
19052557THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOFFebruary 2025September 2025Allow712NoNo
19044731METHOD OF SYNTHESIZING TESTOSTERONE-BASED THIAZOLIDINONE DERIVATIVESFebruary 2025May 2025Allow310YesNo
19039164COMBINATION THERAPY FOR THE TREATMENT OF CANCERJanuary 2025November 2025Abandon910NoNo
190380772,6,9-TRISUBSTITUTED PURINESJanuary 2025August 2025Allow621NoNo
19033289NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECTJanuary 2025July 2025Allow611NoNo
19016827SUBSTITUTED QUINAZOLINES AS HDAC6 INHIBITORSJanuary 2025July 2025Allow610YesNo
19015403SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORSJanuary 2025July 2025Allow610YesNo
18992408PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6-CONTAINING MULTI-COMPONENT MATERIALJanuary 2025October 2025Allow910NoNo
18975881SELECTIVE ANGIOTENSIN II COMPOUNDSDecember 2024July 2025Allow711YesNo
18973867N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATIONDecember 2024May 2025Allow610NoNo
18972557BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERSDecember 2024April 2025Allow501NoNo
18957761COMPOSITION COMPRISING TYROSOL AND AMINO ACIDS AND ITS APPLICATION IN ENHANCING ATHLETIC PERFORMANCE AND COMBATING FATIGUENovember 2024December 2025Allow1221NoNo
18948031CRYSTALLINE FORMS OF 4-ETHOXY-N-(2-METHOXYETHYL)-N-METHYL-3-(5-METHYL-4-OXO-7-PROPYL-3,4-DIHYDROIMIDAZO[5,1-f][1,2,4]TRIAZIN-2-YL)BENZENESULFONAMIDENovember 2024February 2025Allow310YesNo
18934931THIAZOLE COMPOUNDS AND METHODS OF USE THEREOFNovember 2024February 2025Allow401NoNo
18927756BENZOTRIAZOLE COMPOUNDOctober 2024March 2025Allow510NoNo
189273773-(ETHOXYDIFLUOROMETHYL)-6-(5-FLUORO-6-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-3-YL)-[1,2,4]TRIAZOLO[4,3-a]PYRAZINE AS AN ION CHANNEL MODULATOROctober 2024November 2025Allow1320YesNo
18917653NLRP3 INFLAMMASOME INHIBITORSOctober 2024March 2025Allow511YesNo
18906967METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATIONOctober 2024July 2025Allow1020YesNo
18884381AMIDO HETEROAROMATIC COMPOUNDSSeptember 2024March 2025Allow611NoNo
188826491,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOFSeptember 2024February 2025Allow501NoNo
18820993PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECTAugust 2024February 2025Allow510NoNo
18723033SUBSTITUTED MORPHOLINES AS ATR KINASE INHIBITORSAugust 2024June 2025Allow1211YesNo
18838246C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCERAugust 2024April 2025Allow811NoNo
18804311NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE DERIVATIVESAugust 2024January 2025Allow511YesNo
18800565IMIDAZOLO DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTSAugust 2024November 2024Allow311NoNo
18801407PHARMACEUTICAL FORMULATIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERSAugust 2024April 2025Allow800YesNo
18832297PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6-CONTAINING MULTI- COMPONENT MATERIALJuly 2024April 2025Allow910NoNo
18832315PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6 COMPRISING FISHING NETSJuly 2024April 2025Allow910NoNo
18832305PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM POLYAMIDE 6 COMPRISING FISHING NETSJuly 2024March 2025Allow800NoNo
18730504FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTSJuly 2024July 2025Allow1201NoNo
18778527HETEROCYCLIC COMPOUNDS AND USES THEREOFJuly 2024October 2024Allow311NoNo
18777202PARP1 INHIBITORS AND USES THEREOFJuly 2024December 2024Allow510NoNo
18775819FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOFJuly 2024May 2025Allow911NoNo
18770015PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASEJuly 2024July 2025Allow1222YesNo
18764635AMORPHOUS (A-POLYMORPHIC) PSILOCYBINJuly 2024January 2026Allow1821YesNo
18764004CRYSTALLINE SALT FORMS OF KAPPA OPIOID RECEPTOR ANTAGONIST AND PRODUCTS AND METHODS RELATED THERETOJuly 2024August 2024Allow200NoNo
18758953DEUTERIUM-ENRICHED PIPERIDINYL-METHYL-PURINE AMINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONSJune 2024October 2025Allow1531YesNo
18724932PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTSJune 2024December 2024Allow601NoNo
18754527OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOFJune 2024September 2025Allow1521YesNo
18721449SUBSTITUTED PIPERIDINES AND PIPERAZINES AND METHODS FOR THE TREATMENT OF CNS DISORDERSJune 2024April 2025Allow1010YesNo
18745710CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORSJune 2024September 2025Abandon1520NoNo
18741974COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASESJune 2024October 2025Allow1610NoNo
18741572TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYSJune 2024January 2026Allow1910NoNo
18741739PHARMACEUTICAL COMPOSITIONS COMPRISING 4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)-1-(4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)PHENYL)BUTAN-1-ONE FOR TREATING CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AND CARDIAC DISORDERSJune 2024December 2024Allow710YesNo
18740233SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONSJune 2024May 2025Allow1101NoNo
187367105-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTSJune 2024October 2024Allow510NoNo
18675780CRYSTALLINE SOLID FORMS OF A BET INHIBITORMay 2024July 2025Allow1310NoNo
18673619O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORSMay 2024December 2024Allow610YesNo
18668025HETEROCYCLIC COMPOUNDS AND USES THEREOFMay 2024July 2024Allow200NoNo
18662276PHARMACEUTICAL COMPOSITIONS AND CRUSHABLE TABLETS INCLUDING AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USESMay 2024August 2025Allow1510YesNo
18662990COMPOUNDS AS GLP-1R AGONISTSMay 2024July 2025Allow1411NoNo
18661960ESTROGEN RECEPTOR-MODULATING COMPOUNDSMay 2024August 2025Allow1511NoNo
18661650HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERSMay 2024September 2024Allow411NoNo
18661628POLYDENTATE ORGANIC LIGAND, METALLO-SUPRAMOLECULAR POLYMER, POLYMER FILM AND PREPARATION METHOD THEREOFMay 2024September 2025Allow1711NoNo
18661225CRYSTALLINE FORM OF DEURUXOLITINIB PHOSPHATEMay 2024August 2024Allow300YesNo
18658960CRYSTAL FORM OF XEVINAPANT FOR TREATING LA SCCHNMay 2024July 2024Allow300YesNo
18655985MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYEMay 2024February 2026Allow2110NoNo
18656052PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDSMay 2024September 2025Allow1710NoNo
18653538SUBSTITUTED PYRIDINES AS PARP1 INHIBITORSMay 2024May 2025Allow1201YesNo
18652164SOLID FORMS OF ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION AND METHODS OF USE THEREOFMay 2024August 2024Allow410NoNo
18651572SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGSApril 2024October 2025Allow1820NoNo
18651408C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR InhibitorsApril 2024May 2025Allow1300NoNo
18650932TOPICAL PHARMACEUTICAL COMPOSITION IN THE FORM OF AQUEOUS GEL COMPRISING AT LEAST AMITRIPTYLINEApril 2024October 2024Allow610NoNo
18650894TOPICAL PHARMACEUTICAL COMPOSITION IN THE FORM OF AQUEOUS GEL COMPRISING AT LEAST AMITRIPTYLINEApril 2024October 2024Allow610NoNo
18645972CRYSTALLINE CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE AND CRYSTALLINE HYDROCHLORIDE SALTApril 2024July 2024Allow310NoNo
18644056KRAS G12D INHIBITORSApril 2024November 2025Allow1911NoNo
18641842PHEBOX LIGANDS AND METHODS OF MAKING SAMEApril 2024December 2024Allow800NoNo
18642602C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATIONApril 2024December 2025Allow1911NoNo
18639255POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4April 2024June 2024Allow200NoNo
18638558BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOFApril 2024August 2025Allow1611NoNo
18636832PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUNDApril 2024October 2025Abandon1821YesNo
18635839HETEROCYCLIC COMPOUNDApril 2024March 2025Allow1110NoNo
18634259NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOFApril 2024March 2025Abandon1120NoNo
18632213SUBSTITUTED [1,2,4]TRIAZOLO[4,3-C]PYRIMIDINES THAT INDUCE DEGRADATION OF EMBRYONIC ECTODERM DEVELOPMENT (EED) PROTEINApril 2024July 2025Allow1511YesNo
18630109THERAPEUTIC COMPOUNDS AND METHODSApril 2024April 2025Allow1210NoNo
18630561POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITYApril 2024January 2026Abandon2110NoNo
18629648SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTSApril 2024December 2025Allow2020YesNo
18628280SUBSTITUTED PYRIMIDINES AND 1,3,5-TRIAZINES AS RHOJ INHIBITORSApril 2024August 2025Allow1610YesNo
18627407SUBSTITUTED PYRIMIDO[4,5-b]INDOLES AS CK2 INHIBITORSApril 2024March 2025Allow1111YesNo
18627412SUBSTITUTED PYRIMIDO[4,5-b]INDOLES AS CK2 INHIBITORSApril 2024October 2024Allow711YesNo
186257161,3-BIS(NAPHTHALEN-1-YLOXY)PROPAN-2-ONE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)April 2024June 2024Allow200NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1624.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
76
Examiner Affirmed
54
(71.1%)
Examiner Reversed
22
(28.9%)
Reversal Percentile
31.5%
Lower than average

What This Means

With a 28.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1315
Allowed After Appeal Filing
498
(37.9%)
Not Allowed After Appeal Filing
817
(62.1%)
Filing Benefit Percentile
80.1%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 37.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1624 - Prosecution Statistics Summary

Executive Summary

Art Unit 1624 is part of Group 1620 in Technology Center 1600. This art unit has examined 29,126 patent applications in our dataset, with an overall allowance rate of 74.3%. Applications typically reach final disposition in approximately 23 months.

Comparative Analysis

Art Unit 1624's allowance rate of 74.3% places it in the 42% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1624 receive an average of 1.42 office actions before reaching final disposition (in the 17% percentile). The median prosecution time is 23 months (in the 86% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.